Mechanisms to prevent the toxicity of chronic neuroinflammation on forebrain cholinergic neurons

European Journal of Pharmacology

Volumn 402, Issue 1-2, 2000, Pages 77-85

  Wenk, Gary L ^a   McGann, Kristin ^a   Mencarelli, Andrea ^b   Hauss Wegrzyniak, Beatrice ^a   Del Soldato, Piero ^c   Fiorucci, Stefano ^b  

^a UNIVERSITY OF ARIZONA   (United States)

^b Dipto Med Clin Patol Farmacol   (Italy)

^c NicOx SA   (France)

Author keywords

(Rat); Acetylcholine; Caspase; Forebrain basal; Neuroinflammation; Non steroidal anti inflammatory drug

Indexed keywords

3 4[4 [2 FLUORO ALPHA METHYL 1(11' BIPHENYL) 4 ACETYLOXY] 3 METHOXYPHENYL] 2 PROPENOIC ACID 4 NITROOXY)BUTYL ESTER; CASPASE INHIBITOR; FLURBIPROFEN; NCX 2216; NONSTEROID ANTIINFLAMMATORY AGENT; UNCLASSIFIED DRUG;

ACETYLCHOLINE RELEASE; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CHOLINERGIC NERVE CELL; CHRONIC INFLAMMATION; CONTROLLED STUDY; CYTOTOXICITY; DRUG EFFECT; ENZYME ACTIVITY; ENZYME INHIBITION; FOREBRAIN; MICROGLIA; NERVE DEGENERATION; NEUROPROTECTION; NONHUMAN; PRIORITY JOURNAL; RAT; STOMACH MUCOSA;

AMINO ACID CHLOROMETHYL KETONES; ANIMALS; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; BODY WEIGHT; CASPASES; CHOLINE O-ACETYLTRANSFERASE; ENZYME INHIBITORS; FLURBIPROFEN; IMMUNOHISTOCHEMISTRY; INFLAMMATION; LIPOPOLYSACCHARIDES; MALE; NEURONS; PARASYMPATHETIC NERVOUS SYSTEM; PROSENCEPHALON; RATS; RATS, INBRED F344;

EID: 0034683183     PISSN: 00142999     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0014-2999(00)00523-9     Document Type: Article

References (63)

1. Abbas A.K., Lichtman A.H., Pober J.S. Cellular and Molecular Immunology. 1994;Saunders, London.
2. Aisen P.S., Davis K.L. Inflammatory mechanisms in Alzheimer's disease: implications for therapy. Am. J. Psychiat. 151:1994;1105-1113.
3. Akiyama H., Barger S., Barnum S., Bradt B., Bauer J., Cooper N.R., Eikelenboom P., Emmerling M., Fiebich B., Finch C.E., Frautschy S., Griffin W.S.T., Hampel H., Landreth G., McGeer P.L., Mrak R., MacKenzie I., O'Banion K., Pachter J., Pasinetti G., Plata-Salaman C., Rogers J., Rydel R., Shen Y., Streit W., Strohmeyer R., Tooyoma I., Van Muiswinkel F.L., Veerhuis R., Walker D., Webster S., Wegrzyniak B., Wenk G., Wyss-Coray A. Inflammation in Alzheimer's disease. Neurobiol. Aging. 21:2000;383-421.
4. Alnemli E.S., Livingston D.J., Nicholson D.W., Salvesen G., Thornberry N.A., Wong W.W., Yuan J. Human ICE/CED-3 protease nomenclature. Cell. 87:1996;171.
5. Bauer J., Strauss S., Schreiter-Gasser U. Interleukin-6 and γ-2-macroglobulin indicate an acute-phase state in Alzheimer's disease cortices. FEBS Lett. 285:1991;111-114.
6. Bezzi P., Carmignoto G., Pasti L., Vesce S., Rossi D., Rizzini B.L., Pozzan T., Volterra A. Prostaglandins stimulate calcium-dependent glutamate release in astrocytes. Nature. 391:1998;281-285.
7. Blasko I., Schmitt T., Steiner E., Trieb K., Brubeck-Loebenstein B. Tumor necrosis factor alpha augments amyloid beta protein (25-35) induced apoptosis in human cells. Neurosci. Lett. 238:1997;17-20.
8. Bluthe R.-M., Dantzer R., Kelley K.W. Effects of interleukin-1 receptor antagonist on the behavioral effects of lipopolysaccharide in rat. Brain Res. 573:1992;318-320.
9. Chaudhary P.M., Jasmin A., Eby M.T., Hood L. Modulation of the NF-kappa B pathway by virally encoded death effector domains-containing proteins. Oncogene. 18:1999;5738-5746.
10. Davis K.L., Mohs R.C., Marin D., Purohit D.P., Perl D.P., Lantz M., Austin G., Haroutunian V. Cholinergic markers in elderly patients with early signs of Alzheimer disease. JAMA. 281:1999;1401-1406.
11. Dommergues M.-A., Patkai J., Renauld J.-C., Evrard P., Gressens P. Proinflammatory cytokines and interleukin-9 exacerbate excitotoxic lesions of the newborn murine neopallium. Ann. Neurol. 47:2000;54-63.
12. Dubois R.N., Abramson S.B., Crofford L., Gupta R.A., Simon L.S., Van De Putte L.B.A., Lipsky P.E. Cyclooxygenase in biology and disease. FASEB J. 12:1998;1063-1073.
13. Fine S.M., Angel R.A., Perry S.W., Epstein L.G., Rothstein J.D., Dewhurst S., Gelbard H.A. Tumor necrosis factor alpha inhibits glutamate uptake by primary human astrocytes. J. Biol. Chem. 271:1996;15303-15306.
14. Finsen B.R., Jorgensen M.B., Zimmer J. Microglia MHC antigen expression after ischemic and kainic acid lesions of the adult rat hippocampus. Glia. 7:1993;41-49.
15. Fiorucci S., Santucci L., Federici B., Antonelli E., Distrutti E., Morelli O., Renzo G.D., Coata G., Cirino G., Del Soldato P., Morelli A. Nitric oxide-releasing NSAIDs inhibit interleukin-1beta converting enzyme-like cysteine proteases and protect endothelial cells from apoptosis induced by TNF-alpha. Aliment. Pharmacol. Ther. 13:1999;421-435.
16. Fiorucci S., Antonelli E., Santucci L., Morelli O., Miglietti M., Federici B., Mannucci R., Del Soldato P., Morelli A. Gastrointestinal safety of NO-derived aspirin is related to inhibition of ICE-like cysteine proteases. Gastroenterology. 116:1999;1089-1106.
17. Flaris N.A., Densmore T.L., Molleston M.C., Hickey W.F. Characterization of microglia and macrophages in the central nervous system of rats: definition of the differential expression of molecules using standard and novel monoclonal antibodies in normal CNS and in four models of parenchymal reaction. Glia. 7:1993;34-40.
18. Foley P., Bradford H.F., Dochart M., Fillet H., Luine V.N., McEwen B., Buch G., Winblad B., Hardy J. Evidence for the presence of antibodies to cholinergic neurons in the serum of patients with Alzheimer disease. J. Neurol. 235:1988;466-471.
19. Fonnum F. Radiochemical micro assays for the determination of choline acetyltransferase and acetylcholinesterase activities. Biochem. J. 115:1969;465-472.
20. Gahtan E., Overmier J.B. Inflammatory pathogenesis in Alzheimer's disease: biological mechanisms and cognitive sequeli. Neurosci. Biobehav. Rev. 23:1999;615-633.
21. Goossens V., Grooten J., De Vos K., Fiers W. Direct evidence for tumor necrosis factor-induced mitochondrial reactive oxygen intermediates and their involvement in cytotoxicity. Proc. Natl. Acad. Sci. U.S.A. 92:1995;8115-8119.
22. Griffin D.E., Wesselingh S.L., McArthur J.C. Elevated central nervous system prostaglandins in human immunodeficiency virus-associated dementia. Ann. Neurol. 35:1994;592-597.
23. Griffin W.S.T., Sheng J.G., Royston M.C., Gentleman S.M., Mckenzie J.E., Graham D.I., Roberts G.W., Mrak R.E. Glial-neuronal interactions in Alzheimer's disease: the potential role of a "cytokine cycle" in disease progression. Brain Pathol. 8:1998;5-72.
24. Griffin W.S.T., Stanley L.C., Ling C., White L., MacLeod V., Perrot L.J., White C.L. III, Arora C. Brain interleukin-1 and S-100 immunoreactivity are elevated in Down Syndrome and Alzheimer disease. Proc. Natl. Acad. Sci. U.S.A. 86:1989;7611-7615.
25. Hakem R., Hakem A., Duncan G.S., Henderson J.T., Woo M., Soengas M.S., Elia A., de la Pompa J.L., Kagi D., Khoo W., Potter J., Yoshida R., Kaufman S.A., Lowe S.E., Penninger J.M., Mak T.W. Differential requirement for caspase 9 in apoptotic pathways in vivo. Cell. 94:1998;339-352.
26. Harada J., Sugimoto M. Inhibitors of interleukin-1beta-converting enzyme-family proteases (caspases) prevent apoptosis without affecting decreased cellular ability to reduce 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide in cerebellar granule neurons. Brain Res. 793:1998;231-243.
27. Hauss-Wegrzyniak B., Del Soldato P., Pepeu G., Wenk G.L. Peripheral administration of novel anti-inflammatories can attenuate the effect of chronic inflammation within the CNS. Brain Res. 815:1998;36-43.
28. Hauss-Wegrzyniak B., Vraniak P., Wenk G.L. The effects of a novel NSAID upon chronic neuroinflammation are age dependent. Neurobiol. Aging. 20:1999;305-313.
29. 2 in rat astrocyte cultures: modulatory effect of neuropeptides. Endocrinology. 124:1989;3125-3127.
30. Kitagawa H., Takeda F., Kohei H. Effect of endothelium-derived relaxing factor on the gastric lesion induced by HCl in rats. J. Pharmacol. Exp. Ther. 253:1990;1133-1137.
31. Lowry O.H., Rosenbrough N.J., Farr A.L., Randall R.J. Protein measurement with folin phenol reagent. J. Biol. Chem. 193:1951;265-275.
32. MacNaughton W.K., Cirino G., Wallace J.L. Endothelium-derived releasing factor (nitric oxide) has protective actions in the stomach. Life Sci. 45:1989;1869-1876.
33. Masliah E., Mallory M., Alford M., Tanaka S., Hansen L.A. Caspase dependent DNA fragmentation might be associated with excitotoxicity in Alzheimer Disease. J. Neuropathol. Exp. Neurol. 57:1998;1041-1052.
34. McGeer E.G., McGeer P.L. The importance of inflammatory mechanisms in Alzheimer disease. Exp. Gerontol. 33:1998;371-378.
35. McGeer E.G., McGeer P.L. Inflammation of the brain in Alzheimer's disease: implications for therapy. J. Leukocyte Biol. 65:1999;409-415.
36. McGeer P.L., McGeer E.G., Suzuki J., Dolman C.E., Nagai T. Aging, Alzheimer's disease and the cholinergic system of the basal forebrain. Neurology. 34:1984;741-745.
37. McGeer P.L., Akiyama H., Itagaki S., McGeer E.G. Immune system response in Alzheimer's disease. Can. J. Neurol. Sci. 16:1989;516-527.
38. McMillian M., Kong L.-Y., Sawin S.-M., Wilson B., Das K., Hudson P., Hong J.S., Bing G. Selective killing of cholinergic neurons by microglial activation in basal forebrain mixed neuronal/glial cultures. Biochem. Biophys. Res. Commun. 215:1995;572-577.
39. Minghetti L., Levi G. Induction of prostanoid biosynthesis by bacterial lipopolysaccharide and isoproterenol in rat microglial cultures. J. Neurochem. 65:1995;2690-2698.
40. Mrak R.E., Sheng J.G., Griffin W.S.T. Glial cytokines in Alzheimer's disease: review and pathogenic implications. Hum. Pathol. 26:1995;816-823.
41. Muir J.L. Acetylcholine, aging, and Alzheimer's disease. Phamacol. Biochem. Behav. 56:1997;687-696.
42. Murdoch I., Perry E.K., Court J.A., Graham D.I., Dewar D. Cortical cholinergic dysfunction after head injury. J. Neurotrauma. 15:1998;295-305.
43. Namura S., Zhu J., Fink K., Endres M., Srinivasan A., Tomaselli K.J., Yuan J., Moskowitz M.A. Activation and cleavage of caspase-3 in apoptosis induced by experimental cerebral ischemia. J. Neurosci. 18:1998;3659-3668.
44. Oka S., Arita H. Inflammatory factors stimulate expression of group II phospholipase A2 in rat cultured astrocytes. J. Biol. Chem. 266:1991;9956-9960.
45. Perry V.H., Matyszak M.K., Fearn S. Altered antigen expression of microglia in the aged rodent CNS. Glia. 7:1993;60-67.
46. Quan N., Sundar S.K., Weiss J.M. Induction of interleukin-1 in various brain regions after peripheral and central injections of lipopolysaccharide. J. Neuroimmunol. 49:1994;125-134.
47. Rasmusson D.D., Clow K., Szerb J.C. Modification of neocortical acetylcholine release and EEG desynchronization due to brainstem stimulation by drugs applied to the basal forebrain. Neuroscience. 60:1994;665-677.
48. Rasmusson D.X., Brandt J., Martin D.B., Folstein M.F. Head injury as a risk factor in Alzheimer's disease. Brain Inj. 9:1995;213-219.
49. Robinson M.B., Djali S., Buchhalter J.R. Inhibition of glutamate uptake with L-transpyrrolidine-2,4-dicarboxylate potentiates glutamate neurotoxicity in primary hippocampal cultures. J. Neurochem. 61:1993;2099-2103.
50. Rogers J. Inflammation as a pathogenic mechanism in Alzheimer's disease. Drug Res. 45:1995;439-442.
51. Rogers J., Cooper N., Webster S., Schultz J., McGeer P.L., Styren S.D., Civin W.H., Brachova L., Bradt B., Ward P., Lieberburg I. Complement activation by β-amyloid in Alzheimer's disease. Proc. Natl. Acad. Sci. U.S.A. 89:1992;10016-10020.
52. Rothstein J.D., Jin L., Dykes-Hoberg M., Kuncl R.W. Chronic inhibition of glutamate uptake produces a model of slow neurotoxicity. Proc. Natl. Acad. Sci. U.S.A. 90:1993;6591-6595.
53. Shimohama S., Tanino H., Fujimoto S. Changes in caspase expression in Alzheimer's disease: comparison with development and aging. Biochem. Biophys. Res. Comm. 256:1999;381-384.
54. Tan J., Town T., Paris D., Mori T., Suo Z., Crawford F., Mattson M.P., Flavell R.A., Mullan M. Microglial activation resulting from CD40-CD40L interaction after beta-amyloid stimulation. Science. 286:1999;2352-2355.
55. Wallace J.L., Reuter B., Cicala C., McKnight W., Grisham M.B., Cirino G. Novel nonsteroidal anti-inflammatory drug derivatives with markedly reduced ulcerogenic properties in the rat. Gastroenterology. 107:1994;173-179.
56. Wenk G.L., Danysz W., Mobley S.L. MK-801, memantine and amantadine show potent neuroprotective activity against NMDA toxicity in the NBM - A dose response study. Eur. J. Pharmacol. 293:1995;267-270.
57. Wenk G.L., Harrington C.A., Walker L.C., Tucker D.A., Rance N.E. Basal forebrain neurons and memory: a biochemical, histological and behavioral study of differential vulnerability to ibotenate and quisqualate. Behav. Neurosci. 106:1992;909-923.
58. Wenk G.L., Stoehr J.D., Quintana G., Mobley S.L., Wiley R.G. Behavioral, biochemical, histological and electrophysiological effects of 192 IgG-saporin injections into the basal forebrain of rats. J. Neurosci. 14:1994;5986-5995.
59. Wenk G.L., Willard L.B. The neural mechanisms underlying cholinergic cell death within the basal forebrain. Int. J. Dev. Neurosci. 16:1999;729-735.
60. Wenk G.L., Hauss-Wegrzyniak B., Willard L.B. Pathological and biochemical studies of chronic neuroinflammation may lead to therapies for Alzheimer's Disease. Patterson P., Kordon C. Research and Perspectives in Neurosciences: Neuro-Immune Neurodegenerative and Psychiatric Disorders and Neural Injury. 2000;73-77 Springer, Heidelberg.
61. Whitehouse P.J., Price D.L., Clark A.W., Coyle J.T., DeLong M.R. Alzheimer Disease: evidence for selective loss of cholinergic neurons in the nucleus basalis. Ann. Neurol. 10:1981;122-126.
62. Willard L.B., Hauss-Wegrzyniak B., Wenk G.L. The pathological and biochemical consequences of acute and chronic neuroinflammation within the basal forebrain of rats. Neuroscience. 88:1999;193-200.
63. Willard L.B., Hauss-Wegrzyniak B., Danysz W., Wenk G.L. The cytotoxicity of chronic neuroinflammation upon basal forebrain cholinergic neurons of rats can be attenuated by glutamatergic antagonism or cyclooxygenage-2 inhibition. Exp. Brain Res. 2000;. in press.